February 26, 2013: DecImmune Therapeutics announced today that it has completed a $2.25 million equity financing.  The financing is from a new investor Broadview Ventures, along with existing investors Astellas Venture Management and HealthCare Ventures.   The new funds will enable rapid advancement toward IND filing for the company’s proprietary antibody therapeutic to reduce tissue damage and improve ventricular function associated with myocardial infarction.

 

DecImmune-Financing-Press-Release